Oppenheimer raised the firm’s price target on Crinetics to $54 from $48 on higher sales projections in carcinoid, while keeping an Outperform rating on the shares. The firm cites compelling top-line Phase 2 results in carcinoid syndrome – illustrating daily oral paltusotine’s ability to safely reduce the frequency and severity of core clinical features – that follow from December’s positive interim look.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on CRNX:
- Crinetics Pharmaceuticals Advances with Promising Phase 2 Results
- Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
- Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Crinetics price target raised to $50 from $42 at H.C. Wainwright
- Crinetics initiated with a Buy at Citi
